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Abstract
Background: Mitochondrial dysfunction has been implicated in the pathogenesis of Parkinson’s disease (PD). Impairment of
the mitochondrial electron transport chain (ETC) and an increased frequency in deletions of mitochondrial DNA (mtDNA),
which encodes some of the subunits of the ETC, have been reported in the substantia nigra of PD brains. The identification
of mutations in the PINK1 gene, which cause an autosomal recessive form of PD, has supported mitochondrial involvement
in PD. The PINK1 protein is a serine/threonine kinase localized in mitochondria and the cytosol. Its precise function is
unknown, but it is involved in neuroprotection against a variety of stress signalling pathways.
Methodology/Principal Findings: In this report we have investigated the effect of silencing PINK1 expression in human
dopaminergic SH-SY5Y cells by siRNA on mtDNA synthesis and ETC function. Loss of PINK1 expression resulted in a decrease
in mtDNA levels and mtDNA synthesis. We also report a concomitant loss of mitochondrial membrane potential and
decreased mitochondrial ATP synthesis, with the activity of complex IV of the ETC most affected. This mitochondrial
dysfunction resulted in increased markers of oxidative stress under basal conditions and increased cell death following
treatment with the free radical generator paraquat.
Conclusions: This report highlights a novel function of PINK1 in mitochondrial biogenesis and a role in maintaining
mitochondrial ETC activity. Dysfunction of both has been implicated in sporadic forms of PD suggesting that these may be
key pathways in the development of the disease.
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Introduction
Parkinson’s disease (PD) is characterized by loss of dopami-
nergic neurons in the substantia nigra of the brain, with surviving
neurons typically containing intracytoplasmic protein inclusions
known as Lewy bodies [1]. Decreased activity of complex I of the
electron transport chain (ETC) has been reported in PD
substantia nigra [2], while toxins that inhibit complex I, such
as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and rotenone,
can induce parkinsonian features in humans and animal models
[1,3]. Furthermore, deleted mitochondrial DNA (mtDNA) species
have been reported to accumulate in the neurons of PD
substantia nigra [4], while mice with reduced mtDNA copy
number in dopaminergic neurons exhibit a parkinsonian
phenotype [5].
Genes associated with familial forms of PD have also been
shown to effect mitochondrial function [1,6]. In particular, the
identification of mutations in PINK1 has strongly implicated
mitochondrial dysfunction in the pathogenesis of PD [7]. The
PINK1 protein is a serine/threonine kinase that has been
localized to the cytosol and the inner membrane of mitochondria
[8,9]. PINK1 is capable of autophosphorylation [10,11] and has
been shown to be involved in the phosphorylation of the
mitochondrial chaperone TRAP1 [12] and the mitochondrial
protease HtrA2 [13]. Disruption of PINK1-mediated phosphor-
ylation of either TRAP1 or HtrA2 resulted in increased cell death.
Over-expression of wild type PINK1, but not mutant PINK1, also
prevents loss of mitochondrial membrane potential and increased
release of cytochrome-c from mitochondria following stress
[7,14,15].
A PINK1 knockout mouse model has linked PINK1 with a role
in dopamine release and striatal plasticity [16], as well as defects in
mitochondrial respiration [17]. In addition, abnormal mitochon-
drial morphology has been observed in the flight muscles of
Drosophila lacking PINK1, and in human cells either harboring PD-
associated PINK1 mutations or with reduced PINK1 expression
[18–23]. In the Drosophila models, loss of PINK1 function resulted
in mitochondrial dysfunction in flight muscle and loss of
dopaminergic neurons [19,20]. These Drosophila models have also
shown that parkin, another protein associated with familial forms
of PD, acts downstream of PINK1 in a putative common pathway
[18–21].
The dysfunction of mitochondria described above, coupled with
perturbed ETC activity in sporadic PD, prompted us to investigate
the role of PINK1 on oxidative phosphorylation and mitochon-
drial biogenesis in the human dopaminergic SH-SY5Y neuroblas-
toma cell line.
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Cell culture
The human SH-SY5Y neuroblastoma cell line was cultured in
1:1 (v/v) DMEM:F12 (Ham) media containing 0.9 g/l glucose and
supplemented with 10% fetal bovine serum, 1 mM sodium
pyruvate, and penicillin-streptomycin.
For the generation of stable cell lines over-expressing PINK1 or
parkin, SH-SY5Y cells were transfected with pCMV6-Neo vector
(Origene) containing full-length wild type PINK1 cDNA, or
pcDNA3.1 vector (Invitrogen) containing parkin cDNA with a HA
epitope added to the C-terminus. Stable cell lines were selected by
supplementing the media with 40 mg/ml G418. DNA extracted
from both cell lines was sequenced to confirm cDNA sequences.
Over-expression of the respective recombinant proteins was
verified by western blot with a PINK1 antibody (recombinant
PINK1 protein has no epitope tags), or antibodies specific for
parkin or the C-terminus HA epitope tag.
Transient transfection of SH-SY5Y cells with PINK1 siRNA
SH-SY5Y cells (1.8610
5 cells/ml) were transfected with a pair
of PINK1 siRNAs (5 nM each) or 10 nM scrambled control
siRNA (Ambion negative control siRNA #1) using HiPerfect
transfection reagent (Qiagen). Two combinations of PINK1
siRNA were tested, with each siRNA targeting a different region
of PINK1 mRNA. Pair 1 siRNAs (PINK1 #1; sense strands:
GGACGCUGUUCCUCGUUAU and AAGCCACCAUGC-
CUACAUUUU) were designed and synthesized by Dharmacon.
Pair 2 siRNAs (PINK1 #2) were Qiagen HP validated siRNAs
(S100287931, sense strand: GACGCUGUUCCUCGUUAUGAA
and S100287924, sense strand: CCGGACGCUGUUCCUC-
GUUAU). Cells were passaged and transfected with siRNA every
3 days when the cells were 80–90% confluent and in log growth
phase. The transfection efficiency of FAM-labeled negative control
siRNA (Ambion) was .90% after both the first and last
transfection. For SH-SY5Y cells over-expressing recombinant
PINK1, cells were transfected with either 50 nM of the PINK1
siRNA pairs or scrambled control siRNA for 40 hours.
Quantitative real-time PCR of mRNA and mtDNA
RNA was extracted from siRNA-treated cells using the RNeasy
kit (Qiagen) and converted to cDNA by the QuantiTect reverse
transcription kit (Qiagen). mRNA levels were measured by
quantitative real-time PCR (qPCR) using the QuantiTect SYBR
Green kit (Qiagen). For primer sequences see Table S1. GAPDH
was amplified as the reference mRNA. Relative expression was
calculated using the DCT method.
For measurement of mtDNA, total DNA was extracted from
siRNA-treated cells using the QIAamp DNA mini-kit (Qiagen).
MtDNA levels were measured by quantitative real-time PCR
using primers in the D-loop of mitochondria (Table S1) [24].
Amplification of the D-loop of mitochondria was measured using
the QuantiTect SYBR Green kit, and was expressed relative to the
single copy nuclear gene TK2. Relative expression was calculated
using the DCT method.
Radioactive mtDNA synthesis assay
MtDNA synthesis was measured in cells by measuring the
incorporation of [methyl-
3H]thymidine into mtDNA. SH-SY5Y
cells previously treated with siRNA for 72 hours were passaged
into a 24-well plate, transfected with siRNA once more, and
incubated at 37uC for 72 hours. For the last 18 hours, cells
were treated with 10 mg/ml aphidicolin and 5 mCi/well
[methyl-
3H]thymidine (GE Healthcare). Cells were washed three
times with phosphate-buffered saline and lysed overnight in
0.25 M NaOH. A fraction of lysed cells was then spotted onto
DE81 anion exchange paper (Whatman) and washed twice with
300 mM sodium chloride, 30 mM sodium citrate buffer (pH 7.0)
and once with ethanol to remove unincorporated [methyl-
3H]thy-
midine. After drying, the anion exchange paper was placed in
scintillant and radioactivity measured. Each sample was measured
in triplicate. Immunodetection of 5-bromo-29-deoxyuridine incor-
poration indicated that nuclear DNA replication was drastically
inhibited by aphidicolin (Sigma-Aldrich). To allow for nuclear
DNA incorporation that was insensitive to aphidicolin treatment,
[methyl-
3H]thymidine was measured in SH-SY5Y cells lacking
mtDNA (rho zero cells). Incorporation was typically reduced by
.95% in these cells, and was subtracted from the values obtained
for siRNA-treated SH-SY5Y. Data were expressed as
3H counts
per minute incorporated into DNA/mg of protein over an 18-hour
period.
Western blotting
For detection of PINK1 expression, SH-SY5Y cells treated with
siRNA were harvested and lysed on ice with 0.25% (v/v) Triton
X-100 in phosphate-buffered saline, supplemented with protease
inhibitors (1 mM phenylmethanesulfonyl fluoride, 1 mg/ml of
pepstatin A, 1 mg/ml of leupeptin) and 1 mM EDTA for
30 minutes. The soluble fraction (10 mg) was resolved by SDS-
PAGE and transferred to Hybond P (GE Healthcare). Blots were
probed with PINK1 antibody (clone BC100-494, Novus Biolog-
icals) and bands detected by enhanced chemiluminescence
(Pierce). Equal loading was assessed using an antibody against
succinate dehydrogenase subunit SDHA of the electron transport
chain (clone 2E3, Mitosciences).
For the detection of subunit MTCO2 of complex IV (clone
12C4, Mitosciences), porin (clone 89-173/016, Calbiochem) and
TFAM (clone K-18, Santa-Cruz Biotechnology), siRNA-treated
cells were lysed with 1.5% (v/v) n-dodecyl-b-D-maltoside
(Anatrace) in phosphate-buffered saline, supplemented with
protease inhibitors, and processed as above. Equal protein loading
was assessed using a GAPDH antibody (clone 6C5, AbCam).
Density of bands was quantified by AlphaDigiDoc software.
Preparation of blue native gels and subsequent western blotting
is detailed in supplementary Method S1.
Measurement of mitochondrial enzyme activities
Following treatment with siRNA, cells were harvested and
resuspended in isolation medium (320 mM sucrose, 10 mM Tris,
1 mM EDTA, pH 7.4) and activity measured by spectrophoto-
metric methods as previously described [25,26].
Measurement of cellular steady state ATP levels
Following treatment of SH-SY5Y cells with siRNA for 12 days,
cells were trypsinized and resuspended in phosphate-buffered
saline (1610
5 cells/ml). ATP levels were measured using the ATP
Bioluminesence Assay kit HSII (Roche). Each sample was
measured in triplicate. For the oligomycin experiments, cells were
treated with 1 mg/ml of oligomycin for 30 minutes prior to
harvesting cells.
ATP synthesis assay
SH-SY5Y cells were treated with siRNA for 12 days, trypsinized
and washed three times with ice cold phosphate-buffered saline.
Cells were resuspended at 2610
5 cells/ml in incubation medium
(25 mM Tris, 150 mM KCl, 2 mM K
+-EDTA, 10 mM K2HPO4,
pH 7.4). An aliquot of cells (2610
4) was mixed with an equal
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albumin, 1 mM ADP and substrates (complexes I, III, IV:
glutamate+malate (10 mM); complexes II, III, IV: succinate
(10 mM)+rotenone (40 mg/ml); complex IV: ascorbate
(2 mM)+N,N,N9,N9-tetramethyl-p-phenylenediamine (50 mM)),
permeabilized with digitonin (40 mg/ml), and incubated at 37uC
for 20 minutes. The reaction was stopped with perchloric acid,
and samples neutralized with 3 M K2CO3 dissolved in 0.5 M tri-
ethanolamine. Debris was removed by centrifugation and ATP
measured with the ATP Bioluminesence Assay kit HSII. Data
were expressed as pmoles ATP synthesized/minute/10
5 cells. ATP
synthesis was virtually abolished when the assays were performed
with an appropriate inhibitor (e.g. glutamate+malate in the
presence of rotenone). Furthermore, ATP synthesized in cells in
the absence of substrates was #2%, when compared to cells with
substrates.
Assessment of mitochondrial membrane potential
Mitochondrial membrane potential was assessed in SH-SY5Y
cells with the probe JC-1 (Invitrogen). Cells were treated with
siRNA for 12 days in 24-well plates and loaded with 3 mg/ml of
JC-1 for 30 minutes at 37uC. The cells were washed with
phosphate-buffered saline, and mitochondrial JC-1 aggregates
were measured with a fluorescent plate reader (excitation 530 nm,
emission 590 nm). In a sister well, JC-1 fluorescence was measured
in the presence of the ionophore valinomycin (100 nM), which
destroys the mitochondrial membrane potential, and was sub-
tracted from the data. JC-1 fluorescence was expressed against
protein.
Glutathione quantification
Cells treated with siRNA were harvested and the pellet
resuspended in isolation medium. Reduced glutathione (GSH)
levels were determined electrochemically following extraction into
15 mM ortho-phosphoric acid and separation by reverse-phase
high performance liquid chromatography [27].
Detection of protein carbonyls
Protein carbonyl levels were measured in SH-SY5Y treated with
siRNA for 6 or 12 days using the Oxyblot protein oxidation
detection kit (Millipore). Briefly, cells were lysed with 0.25% (v/v)
Triton X-100 in phosphate-buffered saline supplemented with
50 mM DTT and protease inhibitors. Following removal of
insoluble material, protein carbonyls were derivatized to 2,4-
dinitrophenylhydrazone (DNP) by reaction with 2,4-dinitrophe-
nylhydrazine. The DNP-derivatized protein samples were then
separated by SDS-PAGE followed by western blotting. Carbonyls
were detected by incubation with an antibody specific to DNP.
Note that protein samples which were not derivatized to DNP
were not detected by the DNP antibody. Equal loading was
determined by reprobing the same blot with GAPDH antibody.
MitoTracker Green staining of SH-SY5Y cells
The mitochondrial network in live SH-SY5Y treated with
siRNA for 12 days was assessed with MitoTracker Green FM
(Invitrogen). Cells were cultured on coverslips or in 24 well culture
plates and incubated with 5 mg/ml 49-6-diamidino-2-phenylindole
(DAPI) for 2 hours in culture media. The cells were then loaded
with 250 nM MitoTracker Green FM in culture media for
45 minutes at 37uC. Cells were washed once in phenol red free
media and images captured using a Zeiss Axioplan fluorescent
microscope or fluorescence quantified using a fluorescent plate
reader.
Measurement of cell viability and apoptosis
Cell death was measured by the Cell Titer-Blue cell viability
assay (Promega). For the Cell Titer-Blue assay, cells were treated
with or without 0.5 mM paraquat (Aldrich) for 24 hours. For the
last 4 hours, Cell Titer-Blue was added to each well, and
fluorescence measured (excitation 530 nm, emission 590 nm).
The mean fluorescence of three wells was calculated and expressed
as the percentage fluorescence of untreated cells in sister wells.
For the detection of active caspase-3 and cytochrome-c release
from mitochondria, 12-day siRNA-treated cells were grown on
coverslips and treated with 0.5 mM paraquat for the last 24 hours.
Cells were fixed with 3.7% paraformaldehyde, permeabilized with
methanol (220uC) and incubated with anti-cytochrome-c (clone
6H2.B4, BD Biosciences) and anti-active caspase-3 (clone 5A1,
Cell Signaling). Cytochrome-c and active caspase-3 were detected
using goat anti-mouse Alexa 488 and goat anti-rabbit Alexa 568
(Invitrogen), respectively. Nuclei were stained with DAPI, and the
fraction of cells positive for active caspase-3 in each field of view
was determined. The average of five randomly selected fields for
each condition was calculated. Immunofluorescence was per-
formed on four separate siRNA experiments.
Statistical Analysis
Data are expressed as the mean6s.e.m. of separate siRNA
experiments. Statistical significance between PINK1 siRNA-
treated and scrambled control siRNA-treated SH-SY5Y cells
was determined by one-way ANOVA and Tukey HSD test.
Results
Silencing of PINK1 expression
Two different PINK1 siRNA pairs (PINK1 #1 and PINK1 #2)
were used in all experiments in order to confirm that results are a
direct consequence of PINK1 silencing, rather than an off-target
effect. Transfection of SH-SY5Y cells every three days with either
combination of PINK1 siRNA resulted in a sustained decrease in
PINK1 mRNA levels after 6 and 12 days, with mRNA levels
decreased by .80% at both time points (P,0.01; Figure 1A). The
Titer-Blue cell viability assay indicated that silencing of PINK1 for
up to 12 days had no effect on cell death under basal conditions,
when compared to cells transfected with scrambled control siRNA
(PINK1 #1, 65,74964,578 fluorescent units; PINK1 #2,
58,23463,836; control siRNA, 59,68861,351 (mean6s.e.m.,
n=4)).
In agreement with a previous report [28], low levels of
endogenous PINK1 protein expression in SH-SY5Y was detected
by the PINK1 antibody after long exposure (Figure S1). The large
number of non-specific bands, combined with the small amount of
protein obtained from siRNA experiments and difficulties in
solubilizing PINK1 [8,29] meant that reliable detection of PINK1
protein expression following siRNA treatment was not possible.
However, over-expression of full length recombinant PINK1
(,60 kDa) in SH-SY5Y could easily be detected by the PINK1
antibody (Figure 1B and Figure S1). Unfortunately, processed
PINK1 (,55 kDa) co-migrated with a non-specific band (Figure
S1). Recombinant PINK1 mRNA levels were 10-fold higher than
endogenous levels in this cell line. Treatment of these cells with the
two different pairs of PINK1 siRNA reduced PINK1 mRNA levels
by 60% when compared to scrambled control siRNA-treated cells.
This resulted in a decrease in recombinant PINK1 protein
expression, with the PINK1 #2 siRNA pair more effective (52%
decrease compared to scrambled control siRNA; n=3) than
PINK1 #1 siRNA (39% decrease; n=3) (Fig. 1B). This suggests
that silencing of endogenous PINK1 mRNA levels by .80%
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expression.
MtDNA levels and mtDNA synthesis
MtDNA levels were measured in SH-SY5Y cells after silencing
of endogenous PINK1 by quantitative real-time PCR (Figure 2A).
MtDNA levels were significantly decreased with PINK1 #2
siRNA after 6 days (P,0.05), and were depleted by 38% (PINK1
#1) or 42% (PINK1 #2) after 12 days (P,0.01), when compared
to control scrambled siRNA-treated cells. These results were
confirmed by Southern blot, with mtDNA levels decreased by
20.5% and 35.7% in SH-SY5Y treated with PINK1 #1 and #2
siRNA, respectively, for 6 days. Western blotting for mitochon-
drial transcription factor A (TFAM), a protein that binds to
mtDNA and whose expression closely mirrors mtDNA levels [30],
also suggested that mtDNA levels were decreased in PINK1
silenced cells after 12 days (Figure 2B). TFAM protein levels were
decreased by 39% (PINK1 #1) or 30% (PINK1 #2) when
compared to scrambled control siRNA (P,0.05; n=4). The
decreased mtDNA levels were not due to a lower mitochondrial
number. Citrate synthase activity (PINK1 #1, 817.4671.6 nmol/
min/mg protein; PINK1 #2, 799.1695.0; scrambled control
siRNA, 858.16139.6; mean6s.e.m., n=9) were unaffected by
PINK1 silencing. The activity of malate dehydrogenase, another
citric acid cycle enzyme, was also unaffected in PINK1-silenced
cells (PINK1 #1, 13.961.5 mmol/min/mg protein; PINK1 #2,
17.162.0; scrambled control siRNA, 19.760.8; mean6s.e.m.,
n=4). Furthermore, the expression of the mitochondrial protein
porin was similar in both PINK1 #1 and PINK1 #2 siRNA-
treated cells (105% and 99%, respectively), when normalized to
GAPDH expression and compared to control siRNA-treated cells
(Figure 2B). Mitochondrial mass was also determined in live cells
using the specific mitochondrial probe MitoTracker Green FM.
The mitochondrial fluorescence in each well was normalized to
cell number by expressing against DAPI fluorescence. Once again,
there was no difference in mitochondrial fluorescence between
PINK1-siRNA treated and control siRNA-treated cells (PINK1
#1, 1.4160.17; PINK1 #2, 1.5660.23; control siRNA,
1.4660.05 (mean6s.e.m., n=4)).
We next determined whether the lower mtDNA levels in
PINK1-silenced cells was due to a decrease in the rate of mtDNA
synthesis by quantifying the incorporation of [methyl-
3H]thymi-
dine into mtDNA of siRNA-treated cells over an 18-hour period in
the presence of aphidicolin, an inhibitor of nuclear DNA
polymerases. Incorporation of [methyl-
3H]thymidine into mtDNA
of PINK1 #2 siRNA-treated cells was significantly inhibited by
44% (P,0.05; Figure 2C).
The nucleotide 2939-dideoxycytidine (ddC) competitively and
reversibly inhibits DNA polymerase-c (the enzyme responsible for
the synthesis and repair of mtDNA) and is commonly used to
deplete mtDNA levels in cultured cells [31]. In sister wells, cells
were transfected with siRNA as normal, but were cultured in
media containing 10 mM ddC for 6 days. After 6 days, one well
was harvested and mtDNA levels measured by quantitative real-
time PCR, while in the sister well, the ddC was washed away, and
transfected with PINK1 or control siRNA for a further three days
before mtDNA levels were measured. The removal of ddC from
the cell culture media should reverse the inhibition of DNA
polymerase-c during these three days, resulting in de novo mtDNA
synthesis. Following 6 days of siRNA and ddC treatment, mtDNA
levels were depleted to a similar extent in PINK1 and control
siRNA treated cells (PINK1 #1 mtDNA relative expression,
291657; PINK1 #2, 267641; control siRNA, 254662). After the
ddC was washed away, mtDNA levels in control siRNA treated
cells increased by 13%. However, in PINK1-silenced cells,
mtDNA levels continued to decrease (PINK1 #1, 29%; PINK1
#2, 13%) following the removal of ddC, and were significantly
lower than control siRNA-treated cells (P,0.05; Figure 2D). This
result indicates that that de novo mtDNA synthesis was reduced in
PINK1-silenced cells.
Since PINK1 appears to occur upstream of parkin in a signaling
pathway [18–22], and parkin has been implicated in mitochon-
drial biogenesis [32], we investigated whether over-expression of
parkin could reverse the mtDNA depletion observed following
PINK1-silencing. SH-SY5Y cells constitutively over expressing
wild-type parkin were treated with PINK1 or control siRNA for 6
days and mtDNA relative expression measured. MtDNA levels
were decreased by 28% and 40% (P,0.05) in cells treated with
PINK1 #1 and PINK1#2 siRNA, respectively (Figure S2). This
depletion of mtDNA following PINK1-silencing was similar to
parallel experiments in which wild-type SH-SY5Y cells were
treated with PINK1 siRNA (Figure S2). Therefore, this would
suggest that the regulation of mtDNA by PINK1 is not mediated
via parkin.
Mitochondrial ETC activity
Given the decrease in mtDNA levels observed in PINK1-
silenced cells, the activities of the ETC enzyme components were
measured after 6 and 12 days of siRNA treatment, and expressed
against citrate synthase activity. After 6 days of PINK1 silencing,
the activities of complexes I, II+III and IV were all unaffected
(data not shown). However, after 12 days of treatment with PINK1
Figure 1. Silencing of PINK1 mRNA and protein expression in
SH-SY5Y cells. A, SH-SY5Y cells were transfected with PINK1 siRNA
(PINK1 #1 or PINK1 #2) or scrambled control siRNA for 6 or 12 days and
PINK1 mRNA levels measured by reverse transciption and quantitative
real-time PCR. Relative expression was determined against GAPDH
mRNA levels and data were expressed as mean6s.e.m. (n=4). **P,0.01
vs. scrambled control siRNA. B, SH-SY5Y cells over-expressing recom-
binant PINK1 protein were transfected with either PINK1 siRNA (PINK1
#1 or PINK1 #2) or scrambled control siRNA for 40 hours. The
expression of full-length recombinant PINK1 protein was determined in
cell lysates by western blotting. No band was detected in SH-SY5Y
transfected with empty vector. Protein loading was verified with
antibody against succinate dehydrogenase subunit SDHA.
doi:10.1371/journal.pone.0004756.g001
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significantly inhibited by 50% and 55%, respectively (P,0.05;
Table 1). The activities of complexes I and II+III were also lower,
but did not reach significance.
Mitochondrial membrane potential and ATP synthesis
As there was a loss of complex IV activity after 12 days of
silencing, mitochondrial membrane potential was assessed at this
time point using the JC-1 probe. The fluorescence of mitochon-
drial JC-1 aggregates was significantly decreased by 40% (PINK1
#1) or 37% (PINK1 #2) in PINK1-silenced cells (P,0.05;
Figure 3A).
Silencing of PINK1 expression by siRNA in Hela cells has been
reported to fragment the mitochondrial network [22]. Therefore,
live SH-SY5Y cells treated with siRNA for 12 days were stained
Figure 2. Measurement of mtDNA levels and synthesis in PINK1-silenced SH-SY5Y cells. A, SH-SY5Y cells were treated with PINK1 or
scrambled control siRNA for 3, 6, 9 or 12 days and mtDNA levels measured by quantitative real-time PCR. MtDNA levels were expressed relative to the
single copy nuclear gene TK2. Data are expressed as percentage of control siRNA mtDNA levels (n=4). B, cells were treated with siRNA for 12 days
and cell lysates probed for TFAM, GAPDH and porin by western blot. C, SH-SY5Y cells were treated with siRNA for 6 days and de novo mtDNA
synthesis measured by quantifying the incorporation of [methyl-
3H]thymidine into mtDNA over an 18-hour period in the presence of aphidicolin.
Data are expressed as 10
3 counts per minute incorporated per mg of protein and are the mean6s.e.m (n=4). D, SH-SY5Y were treated with PINK1
siRNA for 6 days in the presence of 10 mM ddC, and then the ddC washed away, and the cells incubated for a further 3 days in the presence of siRNA
before mtDNA levels were measured (n=4). * P,0.05 vs. scrambled control siRNA; **P,0.01 vs. scrambled control siRNA.
doi:10.1371/journal.pone.0004756.g002
Table 1. ETC activity in SH-SY5Y cells following 12 days of
PINK1 silencing.
siRNA ETC Activity
II I +III IV
PINK1 #11 4 . 2 64.1 5.461.2 0.06860.012*
PINK1 #21 3 . 6 62.6 4.860.8 0.05960.011*
control 20.166.4 7.561.9 0.13260.024
SH-SY5Y cells were transfected with PINK1 or scrambled control siRNA for 12
days and the activities of complexes I, II+III and IV were measured. Data are
expressed against citrate synthase activity and multiplied by 100. Data are the
mean6s.e.m (n=5)*P,0.05 vs. control siRNA.
doi:10.1371/journal.pone.0004756.t001
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fragmentation of the mitochondrial network was observed
following silencing of PINK1 expression under normal culture
conditions (Figure 3B). Culturing siRNA treated cells in 0.9 g/l
galactose instead of glucose for the last two days of the silencing
experiment also had no effect (data not shown). SH-SY5Y cells
pharmacologically depleted of mtDNA (Rho zero cells) did exhibit
a significant alteration in the mitochondrial network (Figure 3B).
Maintenance of the mitochondrial membrane potential is
essential for the generation of ATP by the ETC. Steady state
cellular ATP levels were decreased by 34% (P,0.05) in PINK1-
silenced cells (Figure 3C). The decrease in ATP levels was due to
decreased mitochondrial synthesis, rather than increased cellular
consumption of ATP (e.g. Na+/K+-dependent ATPases or the
proteasome), as pre-treatment of cells with the ATP synthase
inhibitor oligomycin abolished the difference in ATP levels
between PINK1 and scrambled control siRNA transfected cells.
This was further confirmed by measuring the rate of ATP
synthesis in digitonin permeabilized cells following 12 days of
siRNA treatment. ATP synthesis was significantly inhibited
(P,0.05; n$5) in PINK1-silenced cells by 31% (PINK1 #1) or
24% (PINK1 #2) using glutamate+malate as substrates (complex-
es I, III, IV), 36% (PINK1 #1) or 33% (PINK1 #2) with
succinate+rotenone (complexes II, III, IV), and 53% (PINK1 #1)
or 45% (PINK1 #2) with ascorbate+N,N,N9,N9-tetramethyl-p-
phenylenediamine (complex IV; Figure 3D).
MtDNA transcription and translation
Since mtDNA levels were decreased in PINK1-silenced cells, we
investigated whether the loss of ETC activity was due to decreased
transcription of mtDNA-encoded subunits. Quantitative real-time
PCR of the heavy strand transcripts MTCYTB (complex III) and
MTCO3 (complex IV), and the light strand transcript MTND6
(complex I) were measured in PINK1-silenced cells. After 12 days,
mRNA levels were similar to control siRNA-treated cells (Figure
Figure 3. Mitochondrial membrane potential, morphology and ATP synthesis in PINK1-silenced SH-SY5Y cells. Cells were treated with
PINK1 or scrambled control siRNA for 12 days. A, mitochondrial membrane potential was assessed by measuring the fluorescence of mitochondrial
JC-1 aggregates. Data are expressed against protein and are the mean6s.e.m. (n=5). B, live cells were treated with 250 nM MitoTracker Green and
5 mg/ml DAPI, and color images were captured by fluorescent microscopy. Typical mitochondrial networks found in single cells following control or
PINK1 siRNA treatment are shown in green. The far right panel shows the disruption of the mitochondrial network in cells pharmacologically depleted
of mtDNA (Rho zero cells). The nucleus of each cell is shown in blue. C, steady state cellular ATP levels were measured in siRNA treated cells under
basal conditions or following pre-treatment with 1 mg/ml of oligomycin. Data are the mean6s.e.m.( n=4). D, ATP synthesis was measured in
permeabilized siRNA-treated cells at 37uC using substrates that feed electrons into the electron transport chain at particular points
(glutamate+malate (complex I); succinate+rotenone (complex II) or ascorbate+N,N,N9,N9-tetramethyl-p-phenylenediamine (complex IV)). Data are
the mean6s.e.m. (n$5). * P,0.05 vs. scrambled control siRNA.
doi:10.1371/journal.pone.0004756.g003
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suggested that the significant loss of complex IV activity was not
due to decreased translation (Figure S3B), while blue native gels of
siRNA-treated cells also indicated that PINK1-silencing did not
affect assembly of the complex IV holoenzyme (Figure S3C).
Oxidative stress and cell death
Markers of oxidative stress were assessed in PINK1-silenced
cells. The levels of reduced glutathione, an antioxidant located in
the mitochondria and cytosol, were measured after 6 and 12 days
of PINK1 silencing. Reduced glutathione levels were unaffected
after 6 days of silencing, a time point at which no inhibition of the
ETC was observed. However, reduced glutathione levels were
significantly decreased by 25% (P,0.05) in PINK1-silenced cells
after 12 days (Figure 4A), and was coincident with the decrease in
ETC activity. The protein expression of the mitochondrial
antioxidant enzyme SOD2 was also investigated in cells following
12 days of PINK1-silencing, but was found to be unaffected (data
not shown).
In addition, oxidative stress in SH-SY5Y cells treated with
PINK1 siRNA for 6 or 12 days was assessed by measuring the
carbonylation of proteins by oxidizing species. A marked increase
in carbonylated proteins was observed in PINK1-silenced cells,
when compared to untreated or scrambled control siRNA treated
cells (Figure 4B). When the density of DNP-positive bands in each
lane was measured, and expressed relative to GAPDH, the
Figure 4. Oxidative stress and cell death in PINK1 silenced cells. SH-SY5Y cells were treated with PINK1 or scrambled control siRNA for 12
days. A, reduced glutathione was measured by reverse-phase high performance liquid chromatography. Data are expressed against protein and are
the mean6s.e.m. (n=4). B, the carbonylation of protein residues following PINK1 silencing (#1, #2), or in untreated cells (UT), or cells treated with
control siRNA (C), was determined by Oxyblot. Cells were treated with siRNA for either 6 or 12 days. Loading of Triton X-100 cell lysates was assessed
by re-probing the western blot with GAPDH antibody. C, cell death was measured in siRNA-treated cells by the Cell Titer-Blue assay following
treatment with 0.5 mM paraquat for 24 hours. Data are expressed as percentage of fluorescence of vehicle-treated cells grown in sister wells (n=6).
D, immunofluorescence of cells following treatment with 0.5 mM paraquat for 24 hours. Cells probed for active caspase-3 (red) and cytochrome-c
(green). Cell nuclei were counterstained with DAPI (blue). The inset is shown below. * P,0.05; ** P,0.01 vs. scrambled control siRNA.
doi:10.1371/journal.pone.0004756.g004
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(P,0.01; n=4) by four-fold in cells treated with PINK1 siRNA,
when compared to control siRNA (PINK1 #1, 6.4661.14 relative
intensity; PINK1 #2, 6.2060.11; control siRNA, 1.6160.21).
Considerably lower levels of protein carbonyls were detected in
cells treated with siRNA for 6 days. An exposure time forty times
longer than the 12 day treated samples is shown (Figure 4B). There
is no significant increase in the amount of carbonylated proteins in
cells treated with PINK1 siRNA for 6 days.
As mentioned earlier, cell viability was unaffected in PINK1-
silenced cells grown under basal conditions for 12 days. This was
despite the loss of ETC activity and increased oxidative stress that
occurs at this time point. However, treatment of these cells with
the oxidizing species generator paraquat (0.5 mM) for 24 hours
resulted in a significant decrease in cell viability (P,0.05), when
compared to scrambled control siRNA-transfected cells
(Figure 4C). SH-SY5Y cells transfected with PINK1 siRNA for
12 days also showed increased apoptosis following treatment with
0.5 mM paraquat for 24 hours (Figure 4D, upper panels). The
number of PINK1-silenced cells immunopositive for active
caspase-3 (9.8%) was two-fold higher (P,0.05), compared to
control siRNA-transfected cells (5.0%). Cells expressing caspase-3
showed a release of cytochrome-c from mitochondria and a
fragmentation of nuclei (Fig. 4D, lower panels) further confirming
their apoptotic state. SH-SY5Y cells transfected with PINK1
siRNA for only 6 days (when ETC and markers of oxidative stress
were unaffected) did not show increased sensitivity to paraquat
(data not shown).
Discussion
In this study we report that transfection of dopaminergic SH-
SY5Y cells with PINK1 siRNA results in a progressive loss of
mitochondrial function. We highlight a putative role for PINK1 in
mtDNA synthesis and show for the first time that mitochondrial
dysfunction induced by PINK1 directly results in impaired ATP
synthesis. Dopaminergic neurons are markedly affected in PD.
The loss of PINK1 activity in our dopaminergic cell system has
also confirmed previous reports that have shown that mitochon-
drial dysfunction, and sensitivity to oxidative stress and apoptosis
increases over time in mixed brain cell populations [17,23].
MtDNA has previously been reported to be decreased in
Drosophila not expressing PINK1 [19]. This coincided with a
marked reduction in mitochondrial protein indicating that this
decrease was due to loss of mitochondrial number. Our
experiments suggest that the depletion of mtDNA in SH-SY5Y
cells was due to inhibition of mtDNA synthesis, rather than a loss
of mitochondria. It should be noted that mtDNA levels have been
reported to be unaffected in the fibroblasts of a single PD patient
homozygous for the p.W437X PINK1 nonsense mutation [33].
The mechanism by which PINK1 influences mtDNA is unclear.
The decrease in mtDNA levels precedes the loss of ETC complex
activity, mitochondrial membrane potential and decreased ATP
synthesis. This suggests that the decrease in mtDNA levels is not a
consequence of perturbed oxidative phosphorylation. It should
also be noted that loss of complex IV activity in patients does not
result in decreased mtDNA levels [34].
The regulation of mtDNA levels would also appear not to be
mediated by a PINK1-parkin pathway. Despite parkin being
implicated in mitochondrial biogenesis [32], over expression of
parkin could not reverse mtDNA depletion following silencing of
PINK1. The PINK1-parkin pathway has also been shown to affect
the morphology and dynamics of the mitochondrial network. Our
PINK1-silencing experiments did not result in fragmentation of
the mitochondrial network, as was reported in Hela cells [22], and
can be also be discounted as a reason for mtDNA depletion. The
number of cells required for reliable electron microscopic analysis
of mitochondria following siRNA transfection was not experimen-
tally feasible. Therefore it is unclear whether the mitochondria are
swollen or have disordered cristae as reported previously [21,23].
However, it should be noted that a significant reduction in
mtDNA levels can also alter mitochondrial morphology (Figure 3B)
[35,36].
Phosphorylation pathways have been found to increase mtDNA
levels in vitro [37]. A possible protein downstream of PINK1 is
DNA polymerase-c. This protein is involved in the synthesis and
repair of mtDNA. Mutations in this gene have been associated
with PD [38,39], although not in all studies [40]. HtrA2 is another
protein proposed to be downstream of PINK1 [13]. A recent
report has shown a trend for slightly lower mtDNA levels in the
brains of HtrA2 knock out mice, although it was not significant
[41]. HtrA2 has been proposed to act independently of the
PINK1-parkin pathway [42,43]. Therefore, further investigation
of the PINK1-HtrA2 pathway in dopaminergic cells might
elucidate the mechanism by which PINK1 affects mtDNA levels.
Despite mtDNA levels being depleted in PINK1-silenced cells,
the transcription and translation of mtDNA-encoded subunits
were unaffected. Therefore it does not appear that the decrease in
mtDNA is the cause of the significant decrease in electron
transport chain function observed. Previously it has been reported
that the transcription and translation of mtDNA encoded genes is
unaffected in cells with 50% mtDNA depletion [44,45]. Therefore,
the levels of mtDNA in SH-SY5Y cells following PINK1 silencing
may still be greater than the mitochondrial threshold required for
decreased mitochondrial transcription and translation [46].
In agreement with the results of our PINK1 silencing, Piccoli et
al. [47] have reported a decrease in complex IV activity in skin
fibroblasts derived from a patient homozygous for the PINK1
nonsense mutation p.W437X. A small decrease in complex I
activity has also been observed in fibroblasts from PD patients with
the homozygous p.G309D PINK1 mutation [48]. The recent
finding of impaired mitochondrial respiration in the brains of
PINK1 knock out mice [17] is also in agreement with the
decreased oxidative phosphorylation we observe following PINK1
silencing. As noted above, loss of PINK1 activity affects oxidative
phosphorylation in a variety of cell types. It would be of interest to
determine whether the ETC is more effected in dopaminergic
neurons versus non-dopaminergic neurons.
Phosphorylation of ETC subunits has been shown to increase
ETC activity [37,49]. Therefore the loss of ETC activity following
PINK1 silencing could be due to decreased phosphorylation.
Interestingly, oxidative phosphorylation has also been shown to be
decreased in the brains of HtrA2 knock out mice [41]. This raises
the possibility that a PINK1-HtrA2 pathway might regulate
mitochondrial function. Alternatively, loss of ETC function could
be a result of oxidative modification (see below) or abnormal
mitochondrial morphology.
The silencing of PINK1 in SH-SY5Y cells also resulted in
decreased cellular levels of reduced glutathione, a key antioxidant
in the brain that has been reported to be lower in the substantia
nigra of sporadic PD patients [50]. Total glutathione levels have
been shown to be affected in human neurons with PINK1 knock
down [23] and human fibroblasts expressing the p.G309D PINK1
mutation [48]. Twelve days of PINK1 silencing also resulted in a
significant increase in oxidized protein. Both these markers of
oxidative stress coincided with loss of ETC function. It is unclear
whether the loss of ETC function is a direct cause of the oxidative
stress, or if silencing of PINK1 increases oxidative stress via
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and other cellular components by oxidative modification.
Increasing damage to the ETC components may explain why it
takes twelve days for loss of ETC activity to be observed. It should
be noted that loss of mitochondrial respiration in the brains of
PINK1 knock out mice increases with age, as does sensitivity to
hydrogen peroxide [17], while oxidative modification of complex I
has also been observed in PD brains [51].
The decrease in mitochondrial membrane potential following
PINK1 silencing reported here has also been reported in other
human cell models [22,23]. The mitochondrial membrane
potential is generated by the ETC and is essential for the synthesis
of ATP by mitochondria. Therefore it has been suggested that the
loss of mitochondrial membrane potential observed following
PINK1 silencing will have a significant effect on ATP production,
and thus cellular function and survival. Indeed, a reduction in
ATP levels has been observed in PINK1 fly knock out models that
also exhibit neuronal loss [19,20]. For the first time, we have
demonstrated directly that mitochondrial ATP synthesis is
inhibited in cells depleted of PINK1, and that this event is
concomitant with both a decrease in mitochondrial membrane
potential and inhibition of complex IV of the ETC.
Although mitochondrial dysfunction and oxidative stress occur
after 12 days of PINK1-silencing, there was no effect on cell
viability under basal conditions. However, when these cells were
treated with paraquat, they exhibited increased cell death when
compared to siRNA control cells. A combination of both
decreased ATP production and intracellular oxidative stress most
likely contributes to the increased susceptibility to oxidizing
species. This is supported by the observation that after 6 days of
PINK1 silencing, when no ETC dysfunction or oxidative stress
was observed, there was no increase in sensitivity to paraquat. This
increase in mitochondrial dysfunction and susceptibility to
apoptosis or oxidative stress over time has also been reported in
brain cells with perturbed PINK1 activity [17,23].
In summary, loss of PINK1 activity results in a progressive loss
of mitochondrial function. PINK1 silencing results in decreased
mtDNA levels, impaired oxidative phosphorylation and oxidative
stress. The decreases in mtDNA and ETC activity do not appear
to be directly related. The mechanisms responsible for these two
events are unclear. The loss of mtDNA precedes marked levels of
oxidative stress, and can probably be discounted as a cause.
Conversely, impaired oxidative phosphorylation and increased
oxidative stress coincide. Further experiments are required to
ascertain whether the oxidative stress is a cause or consequence of
ETC inhibition, or an unrelated event. The effects we report
following loss of PINK1 expression are common to events
recognized in sporadic form of PD. Therefore, elucidation of
PINK1 function will probably give a better understanding of the
pathogenic pathways leading to both forms of PD.
Supporting Information
Figure S1 Endogenous and recombinant PINK1 protein
expression in SH-SY5Y cells. SH-SY5Y cells were transfected
with empty vector (pCMV6Neo) or vector containing PINK1
(pCMV6Neo-PINK1). Full-length (60 kDa) and processed
(,55 kDa) recombinant PINK1 were detected by western blotting
and are indicated by an arrow and arrowhead, respectively. Long
exposure yielded a faint band corresponding to full-length
endogenous PINK1 in SH-SY5Y transfected with empty vector.
Asterisk denotes non-specific band co-migrating with processed
PINK1. Equal protein loading was verified by an antibody specific
for the SDH subunit of complex II.
Found at: doi:10.1371/journal.pone.0004756.s001 (0.29 MB TIF)
Figure S2 MtDNA levels in SH-SY5Y cells over-expressing
parkin. SH-SY5Y cells or SH-SY5Y cells over-expressing parkin
were treated with PINK1 siRNA or control siRNA for 6 days, and
mtDNA levels measured by quantitative real-time PCR. MtDNA
levels were expressed relative to the single copy nuclear gene TK2
and are expressed as the mean6SEM (n=4). * P,0.05 vs. SH-
SY5Y treated with scrambled control siRNA; # P,0.05 vs. SH-
SY5Y cells over-expressing parkin treated with scrambled control
siRNA.
Found at: doi:10.1371/journal.pone.0004756.s002 (0.05 MB TIF)
Figure S3 Transcription and translation of mtDNA genes in
PINK1-silenced SH-SY5Y cells. (A) SH-SY5Y cells were treated
with PINK1 or scrambled control siRNA for 12 days and total
cellular RNA extracted. Transcript levels from the mtDNA genes
MTND6, MTCYTB and MTCO3 were measured by qPCR.
mRNA levels were expressed relative to GAPDH mRNA and are
expressed as the mean6SEM (n=3). Protein lysates of SH-SY5Y
cells treated with PINK1 or control siRNA for 12 days were
prepared and separated by SDS-denaturing (B) or blue native gels
(C). Expression of subunit II of complex IV (MTCO2) and
assembled complex IV (CXIV) were then determined by western
blotting. Equal protein loading was verified on each blot with
antibodies specific for porin or complex II (CXII).
Found at: doi:10.1371/journal.pone.0004756.s003 (0.27 MB TIF)
Table S1 Primer sequences for quantitative real time PCR
Found at: doi:10.1371/journal.pone.0004756.s004 (0.03 MB
DOC)
Method S1 Blue native gels. Method for blue native electro-
phoresis that is shown in Figure S3
Found at: doi:10.1371/journal.pone.0004756.s005 (0.02 MB
DOC)
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